Predicting Outcome and Disease Course in acquired demyelinating syndromes in childhood - PROUD-kids 2.0

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 1,200 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Age under 18 years
•2. Auto-immune mediated, demyelinating disorder of the CNS
•3. No other suspected disease causing demyelination in the CNS
•4. Written informed consent is obtained of parents or caregivers. In case the
•patient is 12 years of age or older, the patient needs to provide written
•informed consent as well. , Healthy controls
•1. Age under 18 years
•2. No known systemic auto-immune disease
•3. Full siblings (same father and same mother) of the patient are eligible and
•not blood-related children sharing similar environments (school, neighbourhood
•4. Written informed consent is obtained , Other neurological diseases (OND):
•Patients will be included at the outpatient clinics of pediatric neurologists
•at Erasmus MC-Sophia.
•1. Age under 18 years
•2. No systemic auto-immune disease that might cause inflammatory disease in the
•3. Written informed consent is obtained of parents or caregivers. In case the
•child is 12 years of age or older, the child needs to provide written informed
•consent as well.

•1) Age of onset above 18 years
•2) Inflammation in the CNS by other causes than ADS (for example systemic lupus
•erythematosus, Sj*gren syndrome, sarcoidosis,).
•3) If written informed consent is not obtained.
•4) Withdrawal from study by patient and/or parents.

发起方